



## Antibiotics Use in COVID-19 and Respiratory Tract Infections

Guest Editors:

### Prof. Dr. Shailendra K. Saxena

1. Centre for Advanced Research, Faculty of Medicine, King George's Medical University, Lucknow 226003, India
2. The World Society for Virology, Northampton, MA, USA

### Dr. Swatantra Kumar

1. Centre for Advanced Research, Faculty of Medicine, King George's Medical University (KGMU), Lucknow, India
2. The World Society for Virology, Northampton, MA, USA

Deadline for manuscript  
submissions:

**30 June 2024**

### Message from the Guest Editors

Dear Colleagues,

Coronavirus disease 19 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become an on-going global health emergency with over 94 million cases, and more than 2 million deaths globally. Primarily identified as atypical pneumonia, it has developed into a severe acute respiratory distress syndrome, with multi-organ dysfunction and associated fatality. A rising number of reports have underlined the risk of increasing antimicrobial resistance due to antibiotic overuse in COVID-19 patients. This Special Issue seeks manuscript submissions that further our understanding of antibiotics use and antimicrobial treatment in COVID-19 and respiratory tract infections.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1  
(*General Pharmacology, Toxicology and Pharmaceutics*)

## Contact Us

*Antibiotics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/antibiotics](http://mdpi.com/journal/antibiotics)  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)  
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)